INOVIO (Nasdaq: INO), the makers of the DNA-based vaccine INO-4800, reports positive interim clinical data from the first two Phase 1 clinical trial cohorts. INOVIO has expanded its Phase 1 trial to older participants in additional cohorts and plan on commencing a...
Inovio Pharmaceuticals
Category
INO-4800 COVID-19 Vaccine Candidate: Dark Horse Contender?
Inovio Pharmaceuticals was co-founded by an individual known in scientific circles as “the father of DNA vaccines.” David Weiner, head of Wistar Institute’s Weiner Laboratory, has spent decades working toward this moment in history. Although Inovio’s INO-4800 hasn’t...
Feds Inject $71m Into Inovio Pharmaceuticals to Scale up Manufacturing of Devices Associated with COVID-19 Vaccine
The U.S. Department of Defense (DoD) has injected $71 million of funding into Inovio Pharmaceuticals to support the large-scale manufacture of the company’s proprietary CELLECTRA® 3PSP smart device and the procurement of CELLECTRA 2000 devices, which are used to...
Kansas City MO Clinical Investigator Overseeing Two Vaccines Including Moderna’s mRNA-1273
A Kansas City, Missouri-based clinical investigational site is working overtime during the COVID-19 pandemic, which is quite the opposite for many research sites that saw their work with sponsors crawl to a halt during the slow downs. Alliance for Multispecialty...
INOVIO Pharmaceuticals & Korean Government Close Deal: INO-4800 Phase I/II Trial to Commence in Korea Late June
INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to commence a Phase I/II clinical trial of INO-4800, INOVIO’s COVID-19 vaccine candidate. A formal signing ceremony occurred involving of...
COVID-19 Vaccine INO-4800 Demonstrates Neutralizing Antibody and T-Cell Immune Responses in Preclinical Models
Inovio Pharmaceuticals (Nasdaq: INO) reported recent preclinical data summaries for their COVID-19 DNA vaccine called INO-4800 demonstrating promising information. Namely, the sponsor’s tests demonstrated robust neutralizing antibody and T cell immune responses...
SARS-CoV-2 Vaccine Candidate INO-4800 ‘On Track’ & Headed to Phase II Trials by Summer
Inovio Pharmaceuticals (Nasdaq: “INO”) reports the company’s on track to commence mid-stage study of its INO-4800 vaccine targeting SARS-CoV-2, the virus behind the COVID-19 pandemic. During a first-quarter analyst call this past Monday, the company reports an...
INO-4800 a Leading SARS-CoV-2 Vaccine Candidate: Recent Manufacturing Deal with German Richter-Helm BioLogics GmbH & Co. KG
The race to develop a SARS-CoV-2 vaccine is on and a number of candidates—whether in the UK, U.S. or China—are on the hunt now entering Phase I and even Phase II clinical trials. Philadelphia-area Inovio Pharmaceuticals, according to some, could be in the lead. After...